Polimorfismos genéticos asociados a toxicidad en el tratamiento con 5-fluorouracilo en pacientes con cáncer colorrectal

Cristina  Benavides Tutillo; Gabriela  Molina Pinos; Maritza Raphaela Ochoa Castro

doi:10.33821/568

Polimorfismos genéticos asociados a toxicidad en el tratamiento con 5-fluorouracilo en pacientes con cáncer colorrectal

Cristina Benavides Tutillo, Gabriela Molina Pinos, Maritza Raphaela Ochoa Castro

Universidad de Cuenca

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

Resumen

Colorectal cancer is the most common malignancy of the digestive tract. The treatment is based basically on administering antitumor medications, like 5-fluorouracil (5-FU), which belongs to the antimetabolites, antineoplastic agents. However, it has been shown that there is toxicity related to genetic polymorphism in patients treated with 5-FU, including gastrointestinal symptoms, myelosuppression, and neurotoxicity. The genetic variations of four genes have been studied, including ABCB1, DPYD, MTHFR, and TYMS.

Idioma original	Español (Ecuador)
Publicación	Oncología
DOI	https://doi.org/10.33821/568
Estado	Publicada - 13 ago. 2022

Palabras clave

5-fluorouracilo
5-FU
Cáncer colorrectal
Neoplasias colorrectales
Polimorfismos genéticos

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.33821/568

Otros archivos y enlaces

Other Link

Citar esto

@article{5e9a576572fa4002b422d07bd6f3c46d,

title = "Polimorfismos gen{\'e}ticos asociados a toxicidad en el tratamiento con 5-fluorouracilo en pacientes con c{\'a}ncer colorrectal",

abstract = "Colorectal cancer is the most common malignancy of the digestive tract. The treatment is based basically on administering antitumor medications, like 5-fluorouracil (5-FU), which belongs to the antimetabolites, antineoplastic agents. However, it has been shown that there is toxicity related to genetic polymorphism in patients treated with 5-FU, including gastrointestinal symptoms, myelosuppression, and neurotoxicity. The genetic variations of four genes have been studied, including ABCB1, DPYD, MTHFR, and TYMS.",

keywords = "5-fluorouracilo, 5-FU, C{\'a}ncer colorrectal, Neoplasias colorrectales, Polimorfismos gen{\'e}ticos",

author = "\{Benavides Tutillo\}, Cristina and \{Molina Pinos\}, Gabriela and \{Ochoa Castro\}, \{Maritza Raphaela\}",

year = "2022",

month = aug,

day = "13",

doi = "10.33821/568",

language = "Espa{\~n}ol (Ecuador)",

journal = "Oncolog{\'i}a",

issn = "2661-6653",

}

TY - JOUR

T1 - Polimorfismos genéticos asociados a toxicidad en el tratamiento con 5-fluorouracilo en pacientes con cáncer colorrectal

AU - Benavides Tutillo, Cristina

AU - Molina Pinos, Gabriela

AU - Ochoa Castro, Maritza Raphaela

PY - 2022/8/13

Y1 - 2022/8/13

N2 - Colorectal cancer is the most common malignancy of the digestive tract. The treatment is based basically on administering antitumor medications, like 5-fluorouracil (5-FU), which belongs to the antimetabolites, antineoplastic agents. However, it has been shown that there is toxicity related to genetic polymorphism in patients treated with 5-FU, including gastrointestinal symptoms, myelosuppression, and neurotoxicity. The genetic variations of four genes have been studied, including ABCB1, DPYD, MTHFR, and TYMS.

AB - Colorectal cancer is the most common malignancy of the digestive tract. The treatment is based basically on administering antitumor medications, like 5-fluorouracil (5-FU), which belongs to the antimetabolites, antineoplastic agents. However, it has been shown that there is toxicity related to genetic polymorphism in patients treated with 5-FU, including gastrointestinal symptoms, myelosuppression, and neurotoxicity. The genetic variations of four genes have been studied, including ABCB1, DPYD, MTHFR, and TYMS.

KW - 5-fluorouracilo

KW - 5-FU

KW - Cáncer colorrectal

KW - Neoplasias colorrectales

KW - Polimorfismos genéticos

UR - https://publicaciones.ucuenca.edu.ec/ojs/index.php/quimica/article/view/1792/1508

U2 - 10.33821/568

DO - 10.33821/568

M3 - Artículo

SN - 2661-6653

JO - Oncología

JF - Oncología

ER -